Investor Relations

Corporate Profile

Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts IND-enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of six product candidates, with the option to license eleven more, with lead programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe disease.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Events

Oct 12 - October 16, 2020
2020 Virtual Cell & Gene Meeting on the Mesa
October 5, 2020 at 1:00 PM EDT

lnk Events